<DOC>
	<DOCNO>NCT01461148</DOCNO>
	<brief_summary>Patients advance microsatellite unstable ( MSI-H ) colorectal cancer vaccinate three call frame shift peptide ( FSPs ) , AIM2 ( -1 ) , HT001 ( -1 ) TAF1B ( -1 ) combine Montanide® ISA-51 VG . By , immune response direct MSI-induced FSPs share majority MSI-H colorectal cancer induce . The aim show vaccination MSI-induced FSPs safe induce enhance immune response MSI-H colorectal cancer-associated antigen .</brief_summary>
	<brief_title>Vaccination Against MSI Colorectal Cancer</brief_title>
	<detailed_description>The present study initiate evaluate vaccination MSI-specific FSPs patient MSI-H colorectal cancer . Specifically , present study aim follow question : - Evaluation potential toxicity FSP AIM2 ( -1 ) , HT001 ( -1 ) , TAF1B ( -1 ) - Evaluation immune response patient advance MSI-H colorectal cancer vaccination vaccination FSP AIM2 ( -1 ) , HT001 ( -1 ) , TAF1B ( -1 ) In context , present study shall demonstrate whether application FSP vaccination approach associate induction peptide-related toxicity . Hence , study mark first step towards application FSP human , provide information safety FSP vaccination agent first time . Moreover , study shall provide initial information , whether vaccination FSP induce FSP-specific immune response patient MSI-H colorectal cancer . Thus , shall provide information , whether FSPs AIM2 ( -1 ) , HT001 ( -1 ) , TAF1B ( -1 ) potential elicit peptide-specific immune response therefore represent suitable target induction tumor antigen-specific immune response patient MSI-H tumor . The present study mark important milestone towards potential application MSI-specific FSP therapeutic agent management patient MSI-H tumor , particularly patient MSI-H colorectal cancer . Long-term goal approach develop novel tool ( 1 ) palliative and/or adjuvant therapy patient advance MSI-H colorectal cancer ( 2 ) preventive application FSPs mutation carrier HNPCC/Lynch syndrome .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Phase I part inclusion criterion ( inclusion criterion phase IIa part define later use study amendment ) : Histologically confirm , surgically resect colorectal cancer advance stage ( UICC stage III/UICC stage IV ) . This comprise patient lymph node metastasis ( UICC stage III ) , metastasis one distant organ ( UICC IV , M1a ) , one distant organ , patient peritoneal carcinosis ( UICC IV , M1b ) Detection high level microsatellite instability ( MSIH ) resect tumor sample accord international consensus criterion ( multiplex PCR quasimonomorphic microsatellite marker BAT25 , BAT26 , CAT25 ) , see Appendix 1 . Prior adjuvant standard therapy ( chemotherapy 5fluorouracil/folinic acid , oxaliplatin , irinotecan combination ) OR Prior palliative standard therapy first , second third line ( chemotherapy 5fluorouracil , oxaliplatin , irinotecan combination and/or treatment antiEGFR antibody cetuximab panitumumab alone combination chemotherapy ) either complete partial remission , stable disease , disease progression therapy ; OR Patient refuse adjuvant palliative standard therapy ( chemotherapy use 5fluorouracil , oxaliplatin , regimens combine ) . Expected survival least six month . Full recovery surgery radiation therapy ECOG performance status 0 , 1 2 . The following laboratory result : Neutrophil count ≥ 1.5 x 109/L Lymphocyte count ≥ 0.5 x 109/L Platelet count ≥ 100 x 109/L Serum bilirubin &lt; 2mg/dL Male female patient ≥ 18 year old Last therapy discontinue least 4 week prior vaccination . Patient´s write informed consent participation trial Prior treatment FSPs AIM2 ( 1 ) , HT001 ( 1 ) TAF1B ( 1 ) Clinically significant heart disease ( NYHA Class IV ) . Other serious illness , eg , serious infection require antibiotic bleed disorder . History immunodeficiency disease autoimmune disease . Metastatic disease central nervous system therapeutic option , include radiotherapy , may available . HBV , HCV HIV positivity . Chemotherapy , type radiation therapy , immunotherapy within 4 week study entry Concomitant treatment steroid , antihistaminic drug , nonsteroidal antiinflammatory drug ( unless use low dos prevention acute cardiovascular event pain control ) . Topical inhalational steroid permit . Participation clinical trial Pregnancy lactation . Women childbearing potential use medically acceptable mean contraception . Psychiatric addictive disorder may compromise ability give informed consent . Lack availability patient immunological clinical followup assessment . Brain metastasis ( symptomatic nonsymptomatic )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>UICC stage III/IV MSI-H colorectal cancer</keyword>
</DOC>